SciFluor Life Sciences Expands Senior Management Team with Key Appointments

Adds Industry Experience and Expertise in Medicinal Chemistry, Imaging R&D and Business Development

BOSTON--(BUSINESS WIRE)-- SciFluor Life Sciences, a drug discovery and development company harnessing the transformational power of fluorine to accelerate the development of innovative new therapeutics, today announced the appointments of three industry veterans to its management team. The company has appointed Mark Duggan, Ph.D. as vice president, scientific operations; Scott Edwards, Ph.D. as vice president and general manager, imaging; and Naina Bhasin, Ph.D., as vice president, business development. Together, they join SciFluor with more than 60 combined years of experience in the pharmaceutical, chemical and life sciences industries and proven success in leading innovative medicinal chemistry programs, developing imaging products and forging strategic alliances and industry collaborations.

“We are very pleased to welcome Mark, Scott and Naina to the SciFluor team,” said Arthur Hiller, chief executive officer of SciFluor Life Sciences. “The combination of this talented group of executives and our novel fluorine technologies provides SciFluor with a unique opportunity to establish strategic industry partnerships that have the potential to advance drug discovery and development, and to ultimately improve patient care.”

SciFluor recently announced its second licensing agreement with Harvard University, which grants the company access to technology that enables the rapid, efficient synthesis of 18F -labeled molecules that empower Positron Emission Tomography (PET) imaging for an entirely new level of intelligent, informed and predictive drug development. In 2011, the company announced its first agreement with Harvard – an exclusive, worldwide license to various fluorination methods and to a portfolio of novel fluorinated compounds.

Dr. Duggan joins SciFluor from Link Medicine, Inc., where he served as vice president of chemistry and preclinical development, and as a key member of the executive team. Previously, he served as head of the medicinal chemistry department at Amgen, Cambridge, and spent 18 years at Merck Research Laboratories, where his teams delivered development candidates across the areas of bone biology, endocrinology, oncology and neuroscience. Dr. Duggan is co-inventor of Aggrastat®, has authored more than 50 scientific publications and is an inventor on more than 50 patents. He holds a bachelor’s degree in chemistry from The Pennsylvania State University and a Ph.D. in organic chemistry from the University of Pennsylvania.

Dr. Edwards brings to SciFluor an extensive background in imaging agent research and development with a focus on PET radiopharmaceuticals. Before joining SciFluor, he served as vice president of research and development at Lantheus Medical Imaging. Prior to that role, Dr. Edwards held positions of increasing responsibility in research and development at Bristol-Myers Squibb Medical Imaging and DuPont Medical Imaging. Dr. Edwards holds a bachelor’s degree in chemistry from the Georgia Institute of Technology and a Ph.D. in inorganic chemistry from the Massachusetts Institute of Technology.

Dr. Bhasin joins SciFluor from The Hamner Institutes, a nonprofit research organization in Research Triangle Park, N.C., where she served as vice president of business development and operations. Prior to joining The Hamner Institutes, Dr. Bhasin served as director of the hepatic research registry for CellzDirect, Inc., an in vitro hepatic research company acquired by Invitrogen/Life Technologies. She earned a bachelor’s degree in cell and structural biology at the University of Illinois at Urbana-Champaign and a Ph.D. in cell and developmental biology at the University of North Carolina at Chapel Hill.

About SciFluor Life Sciences, LLC

SciFluor is harnessing the transformational power of fluorine to enrich pipelines, optimize drug discovery and accelerate the clinical development of innovative new therapies. The company’s approach includes a proprietary portfolio of FluoropeuticsTM, fluorine-enabled development candidates targeting a broad range of therapeutic indications; breakthrough fluorine chemistry technology that enables the fluorination of a wide variety of drugs at any stage of development; and novel 18F tracers for empowered PET imaging. SciFluor is funded by Allied Minds, a private equity-funded innovation company that forms, manages and builds startups based on early-stage technology developed at renowned U.S. universities and national labs. The company was founded in 2011 and is based in Boston, Mass. For more information, please visit www.scifluor.com.

About Allied Minds, Inc.

Allied Minds is a private equity-funded innovation company that forms, funds, manages and builds startups based on early-stage technology developed at renowned U.S. universities and national labs. We serve as a diversified holding company that supports our businesses with capital, management and shared services. Allied Minds is the premier firm to utilize this novel and fully-integrated approach to technology commercialization. Our investments span multiple business sectors and offer an attractive risk-return profile, a deliverable timeline and groundbreaking products and services. Our subsidiaries include Allied Minds Devices, BA Logix, Biotectix, Cephalogics, CryoXtract, Illumasonix, ProGDerm, Precision Biopsy, RF Biocidics, SaltCheck, SciFluor Life Sciences, SiEnergy Systems, SoundCure, and Spin Transfer Technologies. We don't just fund the startup. We are the startup. www.alliedminds.com



CONTACT:

Pure Communications, Inc.
Kathryn Cook, 910-509-3976

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Clinical Trials  Hospitals  Medical Devices  Pharmaceutical  Research  Medical Supplies  Science  Physical Therapy

MEDIA:

Logo
 Logo

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.